GNBT: Summary for Generex Biotechnology Corporati - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 4:12am EST - Canadian Markets open in 5 hours and 18 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Generex Biotechnology Corp. (GNBT)

On Nov 23: 0.495 USD 0.00 (0.00%)

MORE ON GNBT

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Generex Biotechnology Corporati (NCM:GNBT) Delayed quote data

Last Trade:	0.495 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	0.495
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	4.63

Day's Range:	N/A - N/A
52wk Range:	0.08 - 1.14
Volume:	0
Avg Vol (3m):	5,477,000
Market Cap:	122.24M
P/E (ttm):	N/A
EPS (ttm):	-0.248
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add GNBT to Portfolio

Download Data

HEADLINES

•	Generex Scientist Makes Presentation at National Influenza Congress
	GlobeNewswire (Mon 10:47am)

•	GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
	EDGAR Online (Tue, Nov 10)

•	Generex has 180 days to regain listing compliance
	AP (Tue, Nov 10)

•	Generex Receives Confirmation of Extension of Compliance Period From NASDAQ
	GlobeNewswire (Tue, Nov 10)

•	Four Biotech Stocks to Play the Sector Pullback
	at Seeking Alpha (Tue, Nov 3)

•	Generex's Glucose RapidSpray(TM) Featured on Doggie Chronicles Radio
	GlobeNewswire (Mon, Nov 2)

•	GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Fri, Oct 30)

•	Generex Announces That It Will Not Exercise Its Rights to Issue and Sell Stock Under Its At Market Issuance Sales Agreement With WM Smith Until Furthe
	GlobeNewswire (Thu, Oct 29)

•	Generex Biotechnology Receives Purchase Order for Generex Oral-lyn(TM) for Algerian Market
	GlobeNewswire (Wed, Oct 21)

•	Generex: Going Concern Qualification
	GlobeNewswire (Tue, Oct 20)

•	GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Tue, Oct 20)

More Headlines for GNBT...

ANALYST

EPS Est (next year) (Jul-08) :	N/A
EPS Est (in 2 years) (Jul-09) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•